v3.26.1
Segments
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Segments Segments
The Company has a single segment and allocates resources based on cash resources and operating expense projections. The table below summarizes the significant expense categories regularly reviewed by the Company’s president and chief executive officer, who is the Company’s chief operating decision maker (“CODM”), for the three and six months ended June 30, 2026 and 2025:
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
Research and development expenses:
Clinical trial expenses:
INVINCIBLE-3 Study (Phase 3 Sarcoma)(a)
$1,132 $788 $1,625 $2,383 
INVINCIBLE-4 Study (Phase 2 Breast)(b)
51 134 169 197 
Other clinical trial expenses— 14 2 14 
Clinical trial expenses1,183 936 1,796 2,594 
Contract manufacturing49 6 82 29 
Salaries and benefits related398 292 727 622 
Consulting and Other(c)
53 44 124 62 
Stock-based compensation150 263 299 423 
Research and development expenses1,833 1,541 3,028 3,730 
General and administrative expenses:
Salaries and benefits related310 234 591 464 
Legal fees82 74 243 243 
Audit fees69 88 158 165 
Consulting158 121 353 317 
Insurance170 160 339 316 
Other(d)
225 106 423 208 
Stock-based compensation237 381 475 656 
General and administrative expenses1,251 1,164 2,582 2,369 
Loss from operations(3,084)(2,705)(5,610)(6,099)
Other segment items(e)
77 168 169 215 
Net loss$(3,007)$(2,537)$(5,441)$(5,884)

(a)In March 2025, the Company paused new site activations and patient enrollments due to funding constraints. In April 2026, the Company initiated plans to resume enrollment in a limited number of U.S. sites.
(b)In September 2025, the Company paused new patient enrollment to revise the dosing regimen for patients receiving INT230-6. In March 2026, a protocol amendment was approved by the Swissmedic and the Swiss Ethics Committee to use a lower drug volume per tumor volume ratio and a single injection of INT230-6 and the Company has resumed enrollment.
(c)Consulting & Other includes research and development consulting costs and travel-related costs.
(d)Other includes facility expenses, office supplies, computer and software related costs, public relations costs, and travel-related costs.
(e)Other segment items include interest income and foreign exchange gains and losses.